Pharmacoeconomic issues of the treatment of gastroesophageal reflux disease

Bibliography

• KLAUSER A, SCHINDLBECK N, MOLLER-LISSNER S: Symptoms in gastro-esophageal reflux disease. Lancet (1990) 335:205–208.
   PubMed Web of Science ®Google Scholar
• •Description of symptoms in GERD.
   Google Scholar
• MEINING A, CLASSEN M: Gastroösophageale RefluxItrankheit. Internist (1998) 39:1215–1222.
   PubMedGoogle Scholar
• SHI G, DES VARANNES SB, SCARPIGNATO C, LE RHUN M, GALMICHE JP: Reflux related symptoms in patients with normal esophageal exposure to acid. Gut (1995) 37:457–464.
   PubMed Web of Science ®Google Scholar
• LIND T, HAVELUND T, CARLSSON R et al: Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scam/. Gastroenterol. (1997) 32:974–979.
   PubMed Web of Science ®Google Scholar
• OLDEN K, TRIADAFILOPOULOS G: Failure of initial 24-hour pH monitoring to predict refractoriness and intractability in reflux esophagitis. Am. I Gastroenterol (1991) 86:1141–1146.
   Google Scholar
• QUIGLEY EMM: 24-hour pH monitoring for gastroesophageal reflux disease: already standard but not yet gold? Am. Gastroenterol (1992) 87:1071–1075.
   Google Scholar
• •Reports the limitations of 24 h pH monitoring.
   Google Scholar
• STORR M, MEINING A, ALLESCHER HD: Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig. Dis. (2000) 18:93–102.
   PubMed Web of Science ®Google Scholar
• SEIGE M, OTT R, ALLESCHER HD: Osophagusmanometrie, 24-Stunden-pH-Metrie und Provokationstests. Verdauungskrankh (1995) 6:215–229.
   Google Scholar
• JOHNSTON BT, COLLINS JS, MCFARLAND RJ, LOVE AH: Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn. Am. Gastroenterol. (1994) 89:497–502.
   PubMedGoogle Scholar
• GUDMUNDSSON K, JOHNSSON LOELSSON B: The time pattern of gastroesophageal reflux. Scam/. Gastroenterol. (1988) 23:75–79.
   PubMedGoogle Scholar
• CASTIGLIONE E EMDE C, ARMSTRONG D et al: Oesophageal pH-metry: should meals be standardized? Scam/. Gastroenterol. (1992) 27:350–354.
   Google Scholar
• PEHL C, PFEIFFER A, WENDL B, KAESS H: The effect of decaffeination of coffee on gastro-esophageal reflux in patients with reflux disease. Aliment. Pharmacol Ther. (1997) 11:483–486.
   PubMedGoogle Scholar
• PEHL C, PFEIFFER A, WENDL B, KAESS H: Different effects of white and red Wine on lower esophageal sphincter pressure and gastroesophageal reflux. Scand. Gastroenterol (1998) 33:118–122.
   PubMedGoogle Scholar
• MEINING A, CLASSEN M: The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am. Gastroenterol (2000) 95:2692–2697.
   PubMed Web of Science ®Google Scholar
• MITTAL R, HOLLOWAY R, PENAGINI R, BLACKSHAW LA, DENT J: Transient lower esophageal sphincter relaxation. Gastroenterology (1995) 109:601–610.
   PubMed Web of Science ®Google Scholar
• HOLLOWAY R, PENAGINI R, IRELAND A: Criteria for objective definition of transient lower esophageal sphincter relaxation. Am. j Physiol. (1995) 268:G128–G133.
   Google Scholar
• MITTAL RK, CHIARELI C, LIU J, SHAKER R: Characteristics of lower esophageal sphincter relaxation induced by pharyngeal stimulation with minute amounts of water. Gastroenterology (1996) 111:378–384.
   PubMedGoogle Scholar
• MITTAL RK, BALABAN DH: The esophagogastric junction. N Engl I Med. (1997) 336:924–932.
   PubMed Web of Science ®Google Scholar
• ••Overview on the physiology of theoesophagogastric junction.
   Google Scholar
• MITTAL RK, LANGE RC, MCCALLUM RW: Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology (1987) 92:130–135.
   PubMed Web of Science ®Google Scholar
• KAHRILAS PJ, SHI G, MANAKA M, JOEHL RJ: Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology (2000) 118:688–695.
   PubMedGoogle Scholar
• STEIN H, DEMEESTER T, HINDER R: Outpatient physiological testing and surgical management of foregut motor disorders. CWT. Probl Surg. (1992) 24:415–455.
   Google Scholar
• KATZ PO, CASTELL DO: GERD during pregnancy. Gastroenterol Chu. North Am. (1998) 27:153–167.
   PubMedGoogle Scholar
• MARSHALL RE, ANGGIANSAH A, MANIFOLD DK, OWEN WA, OWEN WJ: Effect of omeprazole 20 mg twice daily on duodenogastric and gastroesophageal bile reflux in Barrett 's esophagus. Gut (1998) 43:603–606.
   PubMed Web of Science ®Google Scholar
• STORR M, ALLESCHER HD: Esophagealpharmacology and treatment of primary motility disorders. Dis. Esophagus. (1999) 12:241–257.
   PubMed Web of Science ®Google Scholar
• STEIN HJ, BARLOW AE DEMEESTER TR, HINDER RA: Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann. Surg. (1992) 216:35–43.
   Google Scholar
• BRUN J, BENGTSSON L, SORNGARD H: Diagnostic test and treatment of acid related GERD in a general practice population. Gut (1997) 41\(Suppl. 3):A63.
   Google Scholar
• KAHRILAS PJ: Treatment versus management of gastroesophageal reflux disease. Am. J. Gastroenterol (1997) 92:1959–1960.
   PubMedGoogle Scholar
• CHIBA N, DE GARA CJ, WILKINSON JM, HUNT RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 112:1798–1810.
   PubMed Web of Science ®Google Scholar
• ••Substantial meta-analysis on GERDtreatment.
   Google Scholar
• DENT J, BRUN J, FENDRICK AM etal.: An evidence based appraisal of reflux disease management - the Geneval Workshop Report. Gut (1999) 44:S1–S16.
   Google Scholar
• ••The Geneval Workshop Report.
   Google Scholar
• ORR WC, ROBINSON MG, HUMPHRIES TJ, ANTONELLO J, CAGLIOLA A: Dose-response effect of famotidine on patterns of gastro-oesophageal reflux. Aliment. Pharmacol Ther. (1988) 2:229–235.
   PubMed Web of Science ®Google Scholar
• ALLESCHER HD, STOSCHUS B, WUNSCH E, SCHUSDZIARRA V, CLASSEN M: Effect of human gastrin-17 with and without acid suppression on human esophageal motility. Z Gastroenterol (1995) 33:385–391.
   PubMedGoogle Scholar
• PALMER RH, FRANK WO, ROCKHOLD FW, WETHERINTON JD, YOUNG MD: Cimetidine 800 mg twice daily for healing erosions and ulcerations in gastroesophageal reflux disease. Gastroenterology (1990) 12:S29–S34.
   Google Scholar
• SABESIN SM, BERLIN RG, HUMPHRIES TJ, BRADSTREET DC, WALTON-BOWEN KL, ZAIDI S: Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. Arch. Intern. Med. (1991) 151:2394–2400.
   Google Scholar
• SIMON TJ, BERENSON MM, BERLIN RG, SNAPINN S, CAGLIOLA A: Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive esophagitis. Aliment. Pharmacol Ther. (1994) 8:71–79.
   Google Scholar
• TYTGAT GNJ, NICOLAI JJ, REMAN FC: Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology (1990) 99:629–634.
   Google Scholar
• SCHULZE DK: Metoclopramide. Gastroenterology (1979) 77:768–779.
   PubMedGoogle Scholar
• ALBIBI R, MCCALLUM RW: Metoclopramide: pharmacology and clinical application. Ann. Intern. Med. (1983) 98:86–95.
   PubMed Web of Science ®Google Scholar
• KOELZ HR: Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials. Scam/. J Gastroenterol Suppl (1989) 156:25–36.
   PubMedGoogle Scholar
• WEIHRAUCH TR, FORSTER CF, KRIEGLSTEIN J: Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgrad. Med. j (1979) 55\(Suppl. 1):7–10.
   Google Scholar
• CLARKE DE, CRAIG DA, FOZARD JR: The 5-HT4 receptor: naughty, but nice. Trends Pharmacol. Sri. (1989) 10:385–386.
   PubMed Web of Science ®Google Scholar
• CORAZZIARI E, BONTEMPO I, ANZINI F: Effects of cisapride on distal esophageal motility in humans. Dig. Dis. Sci. (1989) 34:1600–1605.
   PubMed Web of Science ®Google Scholar
• ROBERTSON CS, EVANS DF, LEDINGHAM SJ, ATKINSON M: Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol Ther. (1993) 7:181–190.
   PubMedGoogle Scholar
• JANISCH HD, HUTTEMANN W, BOUZO MH: Cisapride versusranitidine in the treatment of reflux esophagitis. Hepatogastroeriterology (1988) 35:125–127.
   PubMedGoogle Scholar
• GILBERT RJ, DODDS WJ, KAHRILAS PJ, HOGAN WJ, LIPMAN S: Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig. Dis. Sci. (1987) 32:1331–1336.
   PubMedGoogle Scholar
• WIENBECK M, LI Q: Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scarid. J Gastroenterol Suppl. (1989) 165:13–18.
   PubMedGoogle Scholar
• RAMPED, ROY ML, DENNIS A, BROWN AM: A mechanism for the proarrythmic effects of cisapride: high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. (1997) 417:28–32.
   PubMedGoogle Scholar
• LAMBERT R: Current practice and future perspectives in the management of gastroesophageal reflux disease. Aliment. Pharmacol. Ther. (1997) 11:651–662.
   PubMedGoogle Scholar
• BATE C, GREEN J, AXON A et al: Omeprazole is more effective than cimetidine for the relief of all grades of GERD associated heartburn, irrespective of the presence or absence of endoscopic esophagitis. Aliment. Pharmacol Ther. (1997) 11:755–763.
   PubMed Web of Science ®Google Scholar
• GALMICHE JP, BARTHELEMY E HAMELIN B: Treating the symptoms of gastroesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment. Pharmacol Ther (1997) 11:765–773.
   PubMed Web of Science ®Google Scholar
• •Double-blind comparison of PPI versus H2-antagonist.
   Google Scholar
• RICHTER JE: Long-term management of gastroesophageal reflux disease and it's complications. Am. J Gastroenterol (1997) 92:30–34.
   Google Scholar
• BATE C, KEELING E CYMORAIN C et al.: Comparison of omeprazole and cimetidine in reflux esophagitis: symptomatic, endoscopic and histological evaluations. Gut (1990) 31:968–972.
   Google Scholar
• SKOUTAKIS V, JOE R, HARA D: Comparative role of omeprazole in the treatment of gastroesophageal reflux disease. Ann. Pharmacother. (1995) 29:1252–1262.
   PubMedGoogle Scholar
• KLINKENBERG-KNOL E, FESTEN H, JANSEN J et al: Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann. Intern. Med. (1994) 121:161–167.
   PubMed Web of Science ®Google Scholar
• •Long-term treatment of reflux oesophagitis.
   Google Scholar
• KLINKENBERG-KNOL E, JANSEN J, LAMERS C, NELIS F, MEUWISSEN S: Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2 receptor antagonist resistant reflux esophagitis. Effects on symptoms, endoscopy, serum gastrin and gastric acid output. Scand. j Gastroenterol (1990) 25:1144–1150.
   Google Scholar
• TYTGAT GNJ: Long-term therapy for reflux esophagitis. N Engl. J Med. (1995) 333:1148–1150.
   PubMedGoogle Scholar
• VIGNERI G, TERMINI R, PILOTTO A et al.: A comparison of five maintenance therapies for reflux esophagitis. N Engl. J Med. (1995) 333:1106–1110.
   PubMed Web of Science ®Google Scholar
• BECK I, CHAMPION M, LEMIRE S, THOMSON A, ANVARI M, ARMSTRONG D: The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease. Can. J Gastroenterol (1997) 11:7–20.
   Google Scholar
• •Canadian consensus on GERD treatment.
   Google Scholar
• PLEIN K, HOTZ J, WURZER H, FUMAGALLI I, TENOR H, SCHNEIDER A: Pantoprazole 20 mg is as effective as pantoprazole 40 mg in prevention of relapse of reflux esophagitis. Gastroenterology (1998) 114:A259.
   Google Scholar
• NANDURKAR S, TALLEY NJ: Epidemiology and natural history of reflux disease. Baillieres Best Pract. Res. an. Gastroenterol (2000) 14:743–757.
   PubMed Web of Science ®Google Scholar
• STORR M, ALLESCHER HD: Barrett-Osophagus, gastroösophagealer Reflux und Helicobacter pylori als Risikofaktoren für das Adenokarzinom der Speiseröhre. Verdauungskrankh (2000) 18:57–62.
   Google Scholar
• SCHINDLBECK NE, KLAUSER AG, VODERHOLZER WA, MOLLER-LISSNER SA: Empiric therapy for gastroesophageal reflux disease. Arch. Intern. Med. (1995) 155:1808–1812.
   PubMed Web of Science ®Google Scholar
• ••Empiric GERD treatment.
   Google Scholar
• MCTAVISH D, BUCKLEY M, HEEL R: Omeprazole - an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs (1991) 42:138–170.
   PubMed Web of Science ®Google Scholar
• YOUNG M, SANOWSKI R, TALBERT G, HARRISON M, WALKER B: Omeprazole administration as a test for gastroesophageal reflux. Gastroenterology (1992) 102:192.
   Google Scholar
• JOHNSSON F, WEYWADT L, SOLHAUG J, HERNQVIST H, BENGTSSON L: One-week omeprazole treatment in the diagnosis of gastro-esophageal reflux disease. Scand. Gastroenterol (1998) 33:20.
   Google Scholar
• BARDHAN KD, HAWKEY CJ, LONG RG et al: Lansoprazole versus ranitidine for the treatment of reflux esophagitis. Aliment. Pharmacol Ther (1995) 9:145–157.
   PubMed Web of Science ®Google Scholar
• EGGLESTON A, WIGERINCK A, HUIJGHEBAERT S, DUBOIS D, HAYCOX A: Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut (1998) 42:13–16.
   PubMed Web of Science ®Google Scholar
• •Cost effectiveness of GERD treatment in clinical practice.
   Google Scholar
• DEVAULT KR, CASTELL DO: ACG treatment guideline: updated guigelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. Gastroenterol. (1999) 94:1434–1442.
   PubMed Web of Science ®Google Scholar
• CARLSSON R, GALMICHE J-P, DENT J, LUNDELL L, FRISON L: Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment. Pharmacol Ther. (1997) 11:473–482.
   PubMedGoogle Scholar
• BATE CM, RICHARDSON PDI: A one year model for the cost-effectiveness of treating reflux esophagitis. Br j Med. Econ. (1992) 2:5–11.
   Google Scholar
• FENNERTY MB: The economics of therapy of gastroesophageal reflux disease. Gastroenterol Int. (1997) 10:126–130.
   Google Scholar
• PHILLIPS C, MOORE A: Trial and error-an expensive luxury: economic analysis of effectiveness of proton pump inhibitors and histamine antagonists in treating reflux disease. Br. J. Med. Econ. (1997) 11:55–63.
   Google Scholar
• •Cost effectiveness: PPI versus H2-antagonists.
   Google Scholar
• BATE CM, RICHARDSON PDI: Cost effectiveness of 20 mg and 40 mg omeprazole in oesophageal reflux disease. Br: J. Med. Econ. (1993) 6:59–66.
   Google Scholar
• LUNDELL L, MIETTINEN P, MYRVOLD HE et al.: Long-term management of gastro-esophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur j Gastroenterol Hepatol. (2000) 12:879–887.
   PubMed Web of Science ®Google Scholar
• LUNDELL L: The knife or the pill in thelong-term treatment of gastroesophageal reflux disease. Yale j Biol. Med. (1994) 67:233.
   PubMedGoogle Scholar
• LUNDELL L: New information relevant to long-term management of endoscopy-negative reflux disease. Aliment. Pharmacol Ther (1997) 11:93–98.
   Google Scholar
• DENT J, YEOMANS ND, MACKINNON M et al.: Omeprazole v ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut (1994) 35:590–598.
   Google Scholar
• HARRIS RA, KUPPERMANN M, RICHTER JE: Prevention of recurrences of erosive esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am. j Med (1997) 102:78–88.
   PubMed Web of Science ®Google Scholar
• STALHAMMAR NO: Assessing the cost-effectiveness of medical treatments in acid-related diseases. The Markov chain approach applied to a comparison between intermittent and maintenance treatment to reflux esophagitis. Land. j Gastroenterol (1993) 28(Suppl.):3–13.
   Google Scholar
• MARKS RD, RICHTER JE, RIZZO Jet al.: Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology (1994) 106:907–915.
   Google Scholar
• DEHN T, SHEPHERD H, COLIN D, KETTLEWELL M, CARROLL N: Double blind comparison of omeprazole versus cimetidine in the treatment of symptomatic erosive reflux esophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut (1990) 31:509–513.
   PubMed Web of Science ®Google Scholar
• RICHTER JE, SABESIN S, KOGUT D, KERR R, WRUBLE L, COLLEN M: Omeprazole versus ranitidine or ranitidind metoclopramide in poorly responsive symptomatic GERD. Am. I Gastroenterol (1996) 91:1766–1772.
   PubMedGoogle Scholar
• BARDHAN KD, MORRIS P, THOMPSON M et al.: Omeprazole in the treatment of erosive esophagitis refractory to high-dose cometidine and ranitidine. Gut (1990) 31:745–749.
   PubMed Web of Science ®Google Scholar
• RICH M, FENDRICK M, CHERNEW ME, BANDEKAR RR, SCHEIMAN JM: Cost-effectiveness of step-up vs. step-down therapy for symptomatic GERD: an international perspective. Gastroenterology (2000) 118\(Suppl. 2):A216–A217.
   Google Scholar
• ARMSTRONG D, BENNETT JR, BLUM AL et al: The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 111:85–92.
   PubMed Web of Science ®Google Scholar
• LOCKE GR, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population study in Olmsted County, Minnesota. Gastroenterology (1997) 112:1448–1456.
   PubMed Web of Science ®Google Scholar